Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 18/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.61 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | KIF23 | Q02241 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5751575 | 0.85 | KIF11 (0.44) | KIF11KCNH2MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL4628175 | 0.80 | KIF11 (0.59) | KIF11KCNH2MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL4879921 | 0.79 | KIF11 (0.80) | KIF11KCNH2MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL4629019 | 0.79 | KIF11 (0.58) | KIF11KCNH2MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL4359320 | 0.78 | KIF11 (0.68) | KIF11KCNH2MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL4629070 | 0.78 | KIF11 (0.57) | KIF11KCNH2MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL5753590 | 0.78 | KIF11 (0.76) | KIF11KCNH2MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL4376437 | 0.78 | KIF11 (0.78) | KIF11KCNH2MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL4595061 | 0.78 | KIF11 (0.72) | KIF11KCNH2MAP1LC3BCYP3A4CYP2C19 | |
| SCHEMBL5406846 | 0.78 | KIF11 (0.56) | KIF11KCNH2MAP1LC3BCYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556357-A4 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2006-09-13 | — | — | EP | disclosed |
| US-7041676-B2 | Compounds, compositions, and methods | CYTOKINETICS, INC. (US) | 2006-05-09 | — | — | US | disclosed |
| US-20060019988-A1 | Compounds for treating cell prolifieration disease with of kinesin activity , anticancer activity | CYTOKINETICS, INC. | 2006-01-26 | — | — | US | disclosed |
| EP-1556357-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2005-07-27 | — | — | EP | disclosed |
| WO-2003106426-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019988-A1 | Compounds for treating cell prolifieration disease with of kinesin activity , anticancer activity | KIF5B, KIF2C, KIF18A | KIF11 5/4885KCNH2 2019/4885MAP1LC3B 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.